

Review Article

Antibiotic Resistance in WHO Priority Bacteria: South-East Asia's Looming Crisis

Viqar Agha^{1*}, Mohini Chaurasia², Zeeshan Fatima³


^{1,2}Era College of Pharmacy, Era University, Sarfarazganj, Lucknow, 226003 (U.P) India.

³Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh Lucknow, India, Sector125, Noida, 201313, India.

Email: ^{1*}viqar.agha@gmail.com

Corresponding Email: ²mohinichaurasia@gmail.com

Received: 08.03.25, Revised: 02.05.25, Accepted: 28.05.25



Graphical Abstract

One of the biggest concerns to world health is still antimicrobial resistance (AMR), which disproportionately affects South and Southeast Asian nations. According to latest WHO research, bacterial AMR is projected to be responsible for approximately 5 million fatalities per year by 2025. Self-medication, illogical antibiotic usage, inadequate sanitation, and unregulated antibiotic use in the poultry, aquaculture, and agricultural sectors all contribute to the acceleration of resistance in these areas. *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneumoniae*, and Gram-positive *Staphylococcus aureus* are among the resistant Gram-negative pathogens that represent a serious threat, according to the World Health Organization's 2024 edition of the Global Priority Pathogens List (GPP). GLASS, the World Health Organization's Global Antimicrobial Resistance and Use Surveillance System has expanded to over 130 countries by 2024, with enhanced modules to monitor antimicrobial use and resistance patterns in real time. Southeast Asia remains a high-risk zone for the appearance and dissemination of multidrug-resistant organisms, including carbapenem-resistant Enterobacteriaceae and colistin-resistant *Acinetobacter* species, with increasing detection of resistance genes such as bla_{NDM-5} and mcr variants. This review highlights the evolving resistance trends in South and Southeast Asia, focusing on high-priority pathogens and their mechanisms of resistance—such as efflux pumps, target modification, and enzymatic degradation. The abstract concludes by stressing the importance of coordinated surveillance, antimicrobial stewardship, cross-border collaboration, and One Health strategies to effectively curb the spread of resistance and safeguard future treatment efficacy.

Keywords; Antimicrobial-resistant, *Acinetobacter baumannii*, *Escherichia coli*, *Klebsiella pneumoniae*, *Staphylococcus aureus*, South East Asia.

INTRODUCTION

Southeast Asian countries are always under scrutiny for developing novel resistant pathogens(1,2), Lack of education, awareness of hygiene, poverty and Antibiotics used in poultry(3), fisheries(4), Disinfectants use in agriculture and environment (5)and irrational use of Antibiotics and irrelevant combinations of antibiotics (6)particularly in Indian market plays a crucial role in proliferation and development of some most virulent and resistant superbugs, in community as well as nosocomial infections, , it is very obvious that it the WHO In 2024 published(7) list of pathogen under classification of critical, high and moderate pathogen most critical (Table 1) are equipped with the strategy of resistant that is Binding site modification(8), Developing efflux pump(9) and Enzymes to Degrade antibiotics(10,11). There is a need to comply with the guidelines of WHO to use antibiotic. And there is an urgent need to regulate the Market of antibiotics in Asia (12). We are racing against the time and our options are getting reduced from time running by. Antimicrobial resistance is a ticking time bomb that are making our chances of survival narrower. It may lead to up "post antimicrobial era" 1.9 million peoples died annually(13) because of Failure of Antimicrobial chemotherapy(14), Common infection may lead to serious consequences, that are difficult to treat with

conventional antibiotics available in the market, that needs to explore novel molecules and other methodologies to combat the infection(15,16), In the current review article, we are discussing the scenario of Asian subcontinent countries, the problem they are facing to cope with multiple drug resistance antimicrobial agents, and the options they are left with, the current available drugs with and novel methods to Counter Superbugs(17,18). Recent studies Shows that resistance to commonly used antibiotics for treating harmful bacteria related to a variety of stomach conditions as more than doubled in 20 years in European countries(19) While overall the risk of both emergence and spread of antibiotic resistance among human is highest in Southeast Asian regions (20) Poor sanitation, low income groups(21), and irrational use of antibiotics ads to the problem many fold in Indian subcontinent including Bangladesh(22), Pakistan and Shri Lanka , environmental factors ,food and probiotics resistance to drugs also responsible for a speeding up and scaling up the process of antimicrobial resistance(23),

WHO Global Priority List Pathogens

In 2024, the World Health Organization (7) (WHO) published a list of global priority pathogens. (24) (GPP) – 12 species of bacteria with critical, high, and medium antibiotic resistance (AR)

Table 1: WHO global priority pathogens list

Priority category	Pathogens	Antibiotic resistance	Grams stain
Critical	Acinetobacter baumannii	Carbapenem-resistant	Gram-negative
	Enterobacterales	Third generation cephalosporin, resistant	Gram-negative
High	Enterobacterales	Third generation Carbapenem, resistant	Gram-negative
	Enterococcus faecium	Vancomycin-resistant	Gram-positive
	Staphylococcus aureus	Methicillin-resistant	Gram-positive
		Vancomycin intermediate and resistant	
	Helicobacter pylori	Clarithromycin-resistant	Gram-negative
	Campylobacter	Fluoroquinolone-resistant	Gram-negative
	Salmonella spp.	Fluoroquinolone-resistant	Gram-negative
	Neisseria gonorrhoeae	Third generation	

	Pseudomonas aeruginosa Shigella spp.	cephalosporin-resistant Carbapenem-resistant Fluoroquinolone-resistant	Gram-negative Gram-negative Gram negative
Medium -	Streptococcus pneumoniae Haemophilus influenza	Penicillin-non-susceptible Ampicillin-resistant	Gram-positive Gram-negative




Figure 1. The graph illustrates antibiotic resistance of *Acinetobacter baumannii* across eight countries in Asia (India, Malaysia, Pakistan, Philippines, Sri Lanka, Taiwan, Thailand, and Vietnam). The y-axis shows the percentage of resistant isolates (% resistant), while the x-axis lists the countries. Each color-coded bar represents resistance to a different antibiotic or antibiotic class.

Acinetobacter baumannii

This bacterium is on priority list of WHO and of various healthcare agency (12). It causes serious infection in lungs, blood, and brain, it also causes urinary tract and sepsis. It is an important opportunistic pathogen that can spread by direct contact and may be found in on the skin or in food, water for soil, it is a and Multiple drug resistant, has emerged as most problematic nosocomial pathogen(25). That maintains with virulence after long time starvation (26) Carbapenems Resistant *Acinetobacter* species Uses three main mechanisms to resist carbapenems, Production of enzyme carbapenemase (27) that hydrolysed Carbapenems (28). Change the function of

membrane associated protein such as porins and activation of drug efflux pump(29) Polymyxin antibiotics are termed as last line of defence, but recently it had been reported that certain strains of *Acinetobacter baumannii* developed resistant against colistin and had been reported in clinical infection sample and faecal survey samples(30) Colistin resistance now increasingly associated with *mcr* gene variants in Asia-Pacific hospitals(31) Immunocompromised individuals are more Likely to be infected with *acinetobacter baumannii*, A zinc efflux system that are likely to aid environmental persistence and host colonization, *A.baumannii* poses broad range of zinc efflux system. that helps the bacteria to

survive in a toxic level of zinc concentration(32) Certain studies shows that 32 mcg/ ml chlorhexidine is sufficient enough to kill Colony forming unit (CFU) of Multiple drug resistant of strains *A. baumannii* on inanimate objects(33) (Figure 1). India and Vietnam show the highest levels of resistance across most antibiotics like aminoglycosides with resistance often exceeding 70%. and >50% to

Carbapenem(34) and Fluroquinolones(35), Thailand and Taiwan exhibit significantly lower resistance, generally below 30% for most antibiotics

Resistance levels are highly variable between countries, indicating possible differences in antibiotic usage, infection control policies, or diagnostic standards




Figure 2. The graph presents antibiotic resistance of *Escherichia coli* across ten countries (India, Malaysia, Pakistan, Philippines, Sri Lanka, Taiwan, Thailand, United States, and Vietnam). The y-axis represents the percentage of resistant isolates (%), while the x-axis shows the countries. Different colored bars represent resistance to different antibiotics or classes.

Escherichia coli is the most abundant enteric bacteria present in the gut of humans and some animals(36), It is one of the predominant pathogens of sepsis and septic shock and an important cause of urinary tract infections (UTIs)(37), enteric infections, and systemic infections. The most serious concern with *Escherichia coli* is its ability to retain resistant genes via horizontal gene exchange (38). *E. coli* emerged as a superbug, with variety of multiple resistance genes, that is extended-spectrum beta-lactamases (ESBL) (39), carbapenemase, aminoglycoside modified enzymes (40) (AME) and Quinolone resistant (41). A single, locally dominant subclone of *Escherichia coli* ST131 has expanded, leading to a higher prevalence of extended range beta-lactamases across Southeast Asia. *Escherichia coli* that produces the NDM-1 gene (*bla*NDM-1) is said to be one of the most important multidrug-resistant bacteria that cause nosocomial infections in

hospital and clinic settings.(42) Among most Problematic Multiple drug resistance organism Polymyxin antibiotics are last line of defence and active against Carbapenem-Resistant Enterobacteriaceae CRE(43) South East Asian countries are often been particularly pointed out to be locus of emerging infections without a proper data in support or may be Inability of these country to collect required data(44) (Figure 2). High resistance to aminopenicillins and 3rd gen cephalosporins in South and Southeast Asia indicates widespread antibiotic misuse (45), possibly due to over-the-counter availability and empirical prescriptions. Carbapenems remain largely effective (46), but signs of emerging resistance (especially in India and Pakistan) are concerning. Aminoglycosides and piperacillin-tazobactam show variable resistance, suggesting regional selection pressure and differential clinical usage. Thailand and the U.S. show comparatively

effective resistance control, likely due to better antibiotic stewardship and healthcare infrastructure. Highlights the urgency for global

and regional AMR (antimicrobial resistance) monitoring, policy reinforcement, and public health interventions




Figure 3. The graph illustrates the percentage of resistant invasive isolates of *Klebsiella pneumoniae* to various antibiotic classes across seven Asian countries: India, Pakistan, Malaysia, Philippines, Taiwan, Thailand, and Vietnam.

Klebsiella pneumoniae considered to be most Invasive and hypervirulent Opportunistic pathogen and is common cause of nosocomial and community acquired bacterial pneumonia infections (47), Urinary tract infection as well as septicaemia and wound infection (48). This bacterium resides in the gut of host while migrating to other parts of the body causes infection. Recently surfaced, leading to hepatic abscesses caused by pyogenic. In chronic alcoholic patients (49). These infections are caused by hypervirulent *K. pneumoniae* (hvKP) isolates. Had been primary reported in south east Asia, In most of the cases of infection found in younger Population in comparison to the old one (50). Hypervirulent strains of *Klebsiella pneumoniae*, which typically lack genes for antibiotic resistance, are linked to virulence plasmids. On the other hand, nosocomial isolates are rarely linked to virulence plasmids but frequently to

resistance...(51) The most unique thing about this bacterium is camouflage that has been acquired during evolutionary mechanism it can escape host immune response and inhibit inflammasome that leads to bacterial dissemination(52) *K. pneumoniae* is resistant to extended spectrum beta lactamase and fluoroquinolones and Carbapenems(20)(53) Low resistance has been reported against Fosfomycin (54) (Figure 3). High carbapenem resistance in countries like Pakistan and India is a public health threat (55), given these are critical antibiotics. Widespread resistance to older drugs (e.g., cephalosporins, amoxicillin-clavulanate) suggests the bacteria have acquired diverse resistance mechanisms. Polymyxin resistance, though generally lower, signals the potential for pan-drug resistant strains. The variation among countries likely reflects differences in antibiotic use, infection control, and healthcare infrastructure (56).




Figure 4. The graph shows the antibiotic resistance profile of *Staphylococcus aureus* isolates across eight countries: India, Malaysia, Philippines, Sri Lanka, Taiwan, Thailand, United States, and Vietnam.

The y-axis represents the percentage of invasive isolates resistant to specific antibiotics or antibiotic classes

Staphylococcus aureus

MARS stands for methicillin-resistant *Staphylococcus aureus*. Lives commensal (57), the primary cause of soft tissue infections, systemic infection of blood (58), osteomyelitis, and endocarditis. MRSA has acquired MGEs with antibiotic resistance genes on various distinct occasions. Erythromycin (*ermC*) (59, 60), clindamycin (constitutively expressed *ermC*), penicillin (*blaZ*) (61), trimethoprim (*dfrA* and *dfrK*), and tetracyclines (*tetK* and *tetL*) resistance, trimethoprim (*dfrA* and *dfrK*), have all been identified (62). *Staphylococcus aureus* capsular polysaccharide is considered to be an important virulence factor under evaluation as vaccine antigen. Studies have identified many genes and pathway involved in production of *S. aureus* capsule but the mechanism by which they regulate the production of capsule during infection remains a mystery,(63) Multidrug efflux pump is behind a major cause of multidrug-resistant. The multidrug efflux pump system embedded in biological membrane of the bacteria and actively removes antimicrobial agents from bacterial cell (64) Methicillin is an antibiotic that is no longer used clinically nowadays MRSA is resistant to antibiotics within same class Such as cephalosporins and carbapenems. Resistance is not due to the

production of Beta lactamase enzyme but rather to the production of modified penicillin binding protein coded on the *mecA* gene.(65) Most of the *staphylococcus aureus* Infection reported worldwide one- half are reported only in Asian countries(66) (figure 4). High MRSA Prevalence: Countries like the Philippines, India, and Vietnam show very high oxacillin resistance (67), indicating widespread MRSA strains. MRSA prevalence is a major concern due to limited treatment options. Vancomycin resistance is consistently low across all countries. This reflects its role as a last-resort treatment for MRSA and its limited use, helping maintain its efficacy. Increasing resistance to fluoroquinolones and aminoglycosides in countries like India and Vietnam is troubling. Resistance to rifampicin is relatively low but rising in certain areas. Better Resistance Profiles in Developed Regions: United States and Taiwan show lower resistance across all categories, likely due to better antibiotic regulation and healthcare infrastructure

WHO's 2024 Updates on Antimicrobial Resistance Surveillance and Stewardship: GLASS Expansion and Global Policy Development?

Worldwide Antimicrobial Resistance and Use Surveillance System (GLASS) expansion

to improve global monitoring of antimicrobial resistance (AMR) and antimicrobial usage (AMU) (68), the World Health Organization (WHO) has greatly extended the Global Antimicrobial Resistance and usage Surveillance System (GLASS). 135 nations, territories, and regions have agreed to contribute data to GLASS on AMR as of December 2023 and/or AMU. In 2024, 130 countries were enrolled in GLASS, with 104 countries submitting national AMR data and 74 countries submitting AMU data at least once between 2021 and 2023.

GLASS now encompasses several modules, including:

Routine surveillance on AMR in common bacterial and fungal pathogens.

Periodic nationally representative surveys to estimate the prevalence and burden of AMR.

Surveillance of AMU in community and hospital settings

In September 2024, WHO launched an updated GLASS data visualization dashboard (69,70), providing interactive visualizations of AMR and AMU data from participating countries? The dashboard summarizes resistance rates for 23 antibiotics across 11 antibacterial classes for 8 bacterial pathogens commonly isolated from patients with bloodstream, gastrointestinal, urinary, or genital infections.

Global Reports on Antimicrobial Stewardship

WHO continues to guide countries in developing and Establishing Antimicrobial Stewardship Programs (ASPs), which are one of the most economical ways to maximize the use of antibiotics, enhance patient outcomes, and lower AMR and infections linked to healthcare. The WHO's updated list of medically important antimicrobials (MIA List) for human medicine was released in 2024. In order to minimize the effect of antimicrobial usage in non-human sectors on AMR in humans, this list functions as a risk management tool to assist in decision-making. The MIA List offers recommendations on the proper use of necessary antibiotics in the human health sector, supplementing the WHO AWaRe (Access, Watch, and Reserve) framework and antibiotic book. Furthermore, Global leaders agreed on a number of goals and initiatives one of which was to reduce the anticipated 4.95 million human deaths from bacterial AMR by 10% by 2030, during the 79th United Nations General Assembly High-Level Meeting on AMR in September 2024. In order to help reach the goal of at least 60% of nations

having funded national action plans on AMR by 2030, the declaration also calls for sustainable national financing and US~\$100 million in catalytic investment.

These developments underscore the global commitment to enhancing AMR (71) surveillance and stewardship (72), providing a robust framework for countries to monitor and combat antimicrobial resistance effectively.

CONCLUSION

Antimicrobial resistance (AMR) continues to escalate as a global health emergency, especially in South and Southeast Asia, where weak regulatory frameworks, The proliferation of resistant organisms is made worse by the overuse of antibiotics and international migration of people and economic activity. As emphasized in the original conclusion, addressing AMR demands collective responsibility at local, regional, and international levels.

In 2024–2025, the World Health Organization made substantial advancements by expanding the Global Antimicrobial Resistance and Use Surveillance System (GLASS) to 130+ countries and updating the Bacterial Priority Pathogens List (BPPL). These initiatives have provided more accurate data to drive policy and clinical interventions. Furthermore, the 2024 UN General Assembly set global targets to minimize AMR-associated mortality by 10% by 2030 and emphasized national action plans with sustainable funding.

To effectively combat AMR, urgent steps are required:

- **Stricter regulation** of antibiotic distribution in human and veterinary sectors.
- **Enhancement of antimicrobial stewardship programs** in both community and hospital settings.
- **Surveillance integration** using platforms like GLASS to monitor resistance trends and antibiotic use.
- **Cross-sector collaboration**, particularly by using the One Health approach, which recognizes the interdependencies of human health, animal health, and the environment.

AMR does not recognize borders; therefore, coordination among nations is not optional but essential. Countries in Asia must align their strategies to share surveillance data, harmonize policy frameworks, and invest in public awareness campaigns, diagnostic capacities,

and the development of novel antimicrobials. Without decisive action, the world risks entering a time beyond antibiotics, when common diseases can no longer be treated

REFERENCES

1. Bhatia R, Narain JP. The growing challenge of antimicrobial resistance in the South-East Asia Region - are we losing the battle? *Indian Journal of Medical Research*. 2010 Nov;132(11):482–6.
2. Goel V, Mathew S, Gudi N, Jacob A, John O. A scoping review on laboratory surveillance in the WHO Southeast Asia Region: Past, present and the future. *J Glob Health*. 2023;13:4028.
3. Nhung NT, Chansiripornchai N, Carrique-Mas JJ. Antimicrobial resistance in bacterial poultry pathogens: A review. Vol. 4, *Frontiers in Veterinary Science*. Frontiers Media S.A.; 2017.
4. Miller RA, Harbottle H. Antimicrobial Drug Resistance in Fish Pathogens. *Microbiol Spectr*. 2018;6(1).
5. McDonnell G, Russell AD. Antiseptics and disinfectants: Activity, action, and resistance. Vol. 12, *Clinical Microbiology Reviews*. 1999. p. 147–79.
6. Singh N, Yeh PJ. Suppressive drug combinations and their potential to combat antibiotic resistance. *Journal of Antibiotics*. 2017 Nov 1;70(11):1033–42.
7. Organization WH. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance [Internet]. World Health Organization; 2024. Available from: <https://books.google.co.in/books?id=UjAJEQAAQBAJ>
8. Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and β -lactam resistance. *FEMS Microbiol Rev*. 2008;32(2):361–85.
9. Costa SS, Viveiros M, Amaral L, Couto I. Multidrug Efflux Pumps in *Staphylococcus aureus*: an Update. *Open Microbiol J*. 2013;7:59–71.
10. Egorov AM, Ulyashova MM, Rubtsova MY. Bacterial Enzymes and Antibiotic Resistance. *Acta Naturae*. 2018;10(4):33–48.
11. Thacharodi A, Lamont IL. Aminoglycoside-Modifying Enzymes Are Sufficient to Make *Pseudomonas aeruginosa* Clinically Resistant to Key Antibiotics. *Antibiotics (Basel)*. 2022 Jul;11(7).
12. Wasan H, Reeta KH, Gupta YK. Strategies to improve antibiotic access and a way forward for lower middle-income countries. *Journal of Antimicrobial Chemotherapy*. 2024;79(1):1–10.
13. Naghavi M, Vollset SE, Ikuta KS, Swetschinski LR, Gray AP, Wool EE, et al. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. *The Lancet [Internet]*. 2024 Sep 28;404(10459):1199–226. Available from: [https://doi.org/10.1016/S0140-6736\(24\)01867-1](https://doi.org/10.1016/S0140-6736(24)01867-1)
14. Fernandes P, Martens E. Antibiotics in late clinical development. *Biochem Pharmacol*. 2017;133:152–63.
15. Frieri M, Kumar K, Boutin A. Antibiotic resistance. *J Infect Public Health*. 2017;10(4):369–78.
16. Brüssow H. The antibiotic resistance crisis and the development of new antibiotics. *Microb Biotechnol*. 2024;17(7):e14510.
17. Rajendran R. Superbug Infection. *J Drug Metab Toxicol*. 2018 Jun 20;09(02):1–3.
18. Chandrasekhar D, Joseph CM, Murali S, Yahiya M. Superbugs: An invincible threat in post antibiotic era. *Clin Epidemiol Glob Health*. 2024;28:101499.
19. Resistance to antibiotics doubles in 20 years, new study finds | EurekaAlert! Science News [Internet]. [cited 2019 Oct 28]. Available from: https://www.eurekaalert.org/pub_releases/2019-10/sh-rta101419.php
20. Chereau F, Opatowski L, Tourdjman M, Vong S. Risk assessment for antibiotic resistance in South East Asia. *BMJ (Online)*. 2017;358:2–8.
21. Zellweger RM, Carrique-Mas J, Limmathurotsakul D, Day NPJ, Thwaites GE, Baker S, et al. A current perspective on antimicrobial resistance in Southeast Asia. *Journal of Antimicrobial Chemotherapy*. 2017;72(11):2963–72.
22. Ahmed I, Rabbi MB, Sultana S. Antibiotic resistance in Bangladesh: A systematic review. Vol. 80, *International Journal of Infectious Diseases*. Elsevier B.V.; 2019. p. 54–61.
23. Mitra S, Sultana SA, Prova SR, Uddin TM, Islam F, Das R, et al. Investigating

- forthcoming strategies to tackle deadly superbugs: current status and future vision. *Expert Rev Anti Infect Ther*. 2022;20(10):1309–32.
24. Asokan G V., Ramadhan T, Ahmed E, Sanad H. WHO global priority pathogens list: A bibliometric analysis of medline-pubmed for knowledge mobilization to infection prevention and control practices in Bahrain. Vol. 34, *Oman Medical Journal*. Oman Medical Specialty Board; 2019. p. 184–93.
25. Jeong GJ, Khan F, Tabassum N, Kim YM. Motility of *Acinetobacter baumannii*: regulatory systems and controlling strategies. *Appl Microbiol Biotechnol*. 2024;108(1):3.
26. Chapartegui-González I, Lázaro-Díez M, Bravo Z, Navas J, Icardo JM, Ramos-Vivas J. *Acinetobacter baumannii* maintains its virulence after long-time starvation. *PLoS One*. 2018 Aug 1;13(8).
27. Igbokwe NH, Ezenwaji CK, Ezejiegu CK, Oli AN. The prevalence of *Klebsiella pneumoniae* Carbapenemase and Metallo-beta-lactamases/Oxacillinase enzymes in drug-resistant bacterial isolates from students' toilet facilities in a Nigerian pharmacy school. *World Journal of Applied Science & Technology*. 2025;22(1):4642–53.
28. Paudel R, Shrestha E, Chapagain B, Tiwari BR. Carbapenemase Producing Gram Negative Bacteria: Review of Resistance and Detection Methods. *Diagn Microbiol Infect Dis*. 2024;116370.
29. Sen B, Joshi SG. Studies on *Acinetobacter baumannii* involving multiple mechanisms of carbapenem resistance. *J Appl Microbiol*. 2016 Mar;120(3):619–29.
30. Li S, Duan X, Peng Y, Rui Y. Molecular characteristics of carbapenem-resistant *Acinetobacter* spp. from clinical infection samples and fecal survey samples in Southern China. *BMC Infect Dis*. 2019 Dec 28;19(1):900.
31. Singh S, Sahoo RK, Sahu MC. Understanding Recent Developments in Colistin Resistance: Mechanisms, Clinical Implications, and Future Perspectives. 2025;
32. The role of zinc efflux during *Acinetobacter baumannii* infection. - PubMed - NCBI [Internet]. [cited 2019 Nov 4]. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/31658418>
33. Biswas D, Tiwari M, Tiwari V. Molecular mechanism of antimicrobial activity of chlorhexidine against carbapenem-resistant *Acinetobacter baumannii*. Tripathi T, editor. *PLoS One*. 2019 Oct 29;14(10):e0224107.
34. Chen CH, Wu PH, Lu MC, Ho MW, Hsueh PR. Geographic patterns of carbapenem-resistant, multi-drug-resistant and difficult-to-treat *Acinetobacter baumannii* in the Asia-Pacific region: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. *Int J Antimicrob Agents*. 2023;61(2):106707.
35. Gandra S, Alvarez-Uria G, Turner P, Joshi J, Limmathurotsakul D, van Doorn HR. Antimicrobial resistance surveillance in low-and middle-income countries: progress and challenges in eight South Asian and Southeast Asian countries. *Clin Microbiol Rev*. 2020;33(3):10–1128.
36. Pitout JD, Laupland KB. Extended-spectrum β -lactamase-producing *Enterobacteriaceae*: an emerging public-health concern. Vol. 8, *The Lancet Infectious Diseases*. 2008. p. 159–66.
37. Pitout JDD. Extraintestinal pathogenic *Escherichia coli*: A combination of virulence with antibiotic resistance. Vol. 3, *Frontiers in Microbiology*. Frontiers Research Foundation; 2012.
38. Croxen MA, Finlay BB. Molecular mechanisms of *Escherichia coli* pathogenicity. Vol. 8, *Nature Reviews Microbiology*. 2010. p. 26–38.
39. Ramadan AA, Abdelaziz NA, Amin MA, Aziz RK. Novel blaCTX-M variants and genotype-phenotype correlations among clinical isolates of extended spectrum beta lactamase-producing *Escherichia coli*. *Sci Rep*. 2019 Dec 1;9(1).
40. Nguyen DT. Susceptibility of *Escherichia Coli* Isolated from the Urine of Patients with Urinary Tract Infection in Vietnam to Trimethoprim-Sulfamethoxazole, Nitrofurantoin, Fosfomycin, Aminoglycosides, and Fluoroquinolones: A Systematic Review and Meta-Analysis. Nitrofurantoin, Fosfomycin, Aminoglycosides, and Fluoroquinolones: A Systematic Review and Meta-Analysis.
41. Cometta A, Calandra T, ... *JBNEJ of*, 1994 undefined. *Escherichia coli* resistant to

- fluoroquinolones in patients with cancer and neutropenia. Mass Medical Soc.
42. Chen SL, Ding Y, Apisarnthanarak A, Kalimuddin S, Archuleta S, Omar SFS, et al. The higher prevalence of extended spectrum beta-lactamases among *Escherichia coli* ST131 in Southeast Asia is driven by expansion of a single, locally prevalent subclone. *Sci Rep*. 2019 Dec;9(1).
43. Li Z, Cao Y, Yi L, Liu JH, Yang Q. Emergent Polymyxin Resistance: End of an Era? *Open Forum Infect Dis*. 2019 Oct 1;6(10).
44. Malchione MD, Torres LM, Hartley DM, Koch M, Goodman JL. Carbapenem and colistin resistance in Enterobacteriaceae in Southeast Asia: Review and mapping of emerging and overlapping challenges. *Int J Antimicrob Agents*. 2019 Oct 1;54(4):381–99.
45. Salleh MZ, Zuraina NMNN, Deris ZZ, Mohamed Z. Current trends in the epidemiology of multidrug-resistant and beta-lactamase-producing *Pseudomonas aeruginosa* in Asia and Africa: a systematic review and meta-analysis. *PeerJ*. 2025;13:e18986.
46. Miyoshi-Akiyama T, Thanh D Van, Phuong TT, Huy NQ, Thuy PTP, Kirikae T, et al. Molecular Epidemiology of *Escherichia coli* Resistant to Carbapenems, Fluoroquinolones, and Aminoglycosides Isolated from One of the Largest Hospitals in Vietnam in 2014–2019. *Canadian Journal of Infectious Diseases and Medical Microbiology*. 2024;2024.
47. Han X, Yao J, He J, Liu H, Jiang Y, Zhao D, et al. Clinical and laboratory insights into the threat of hypervirulent *Klebsiella pneumoniae*. *Int J Antimicrob Agents*. 2024;107275.
48. Heidary M, Nasiri MJ, Dabiri H, Tarashi S. Prevalence of Drug-resistant *Klebsiella pneumoniae* in Iran: A Review Article. *Iran J Public Health*. 2018 Mar;47(3):317–26.
49. Podschun R, Ullmann U. *Klebsiella* spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. Vol. 11, *Clinical Microbiology Reviews*. 1998. p. 589–603.
50. Struve C, Roe CC, Stegger M, Stahlhut SG, Hansen DS, Engelthaler DM, et al. Mapping the evolution of hypervirulent *Klebsiella pneumoniae*. *mBio*. 2015 Jul 21;6(4).
51. Turton J, Davies F, Turton J, Perry C, Payne Z, Pike R. Hybrid Resistance and Virulence Plasmids in “High-Risk” Clones of *Klebsiella pneumoniae*, Including Those Carrying blaNDM-5. *Microorganisms*. 2019 Sep 6;7(9):326.
52. Codo AC, Saraiva AC, dos Santos LL, Visconde MF, Gales AC, Zamboni DS, et al. Inhibition of inflammasome activation by a clinical strain of *Klebsiella pneumoniae* impairs efferocytosis and leads to bacterial dissemination. *Cell Death Dis*. 2018 Dec 1;9(12).
53. Wiener ES, Heil EL, Hynicka LM, Kristie Johnson J. Are fluoroquinolones appropriate for the treatment of extended-spectrum β -lactamase-producing gram-negative bacilli? *Journal of Pharmacy Technology*. 2016 Feb 1;32(1):16–21.
54. Caneiras C, Lito L, Melo-Cristino J, Duarte A. Community- and Hospital-Acquired *Klebsiella pneumoniae* Urinary Tract Infections in Portugal: Virulence and Antibiotic Resistance. *Microorganisms*. 2019 May 16;7(5):138.
55. Aslam B, Rasool M, Muzammil S, Siddique AB, Nawaz Z, Shafique M, et al. Carbapenem resistance: Mechanisms and drivers of global menace. In: *Pathogenic Bacteria*. IntechOpen; 2020.
56. Apisarnthanarak A, Kwa ALH, Chiu CH, Kumar S, Thu LTA, Tan BH, et al. Antimicrobial stewardship for acute-care hospitals: an Asian perspective. *Infect Control Hosp Epidemiol*. 2018;39(10):1237–45.
57. Dhungel S, Rijal KR, Yadav B, Dhungel B, Adhikari N, Shrestha UT, et al. Methicillin-Resistant *Staphylococcus aureus* (MRSA): Prevalence, Antimicrobial Susceptibility Pattern, and Detection of mec A Gene among Cardiac Patients from a Tertiary Care Heart Center in Kathmandu, Nepal. *Infectious Diseases: Research and Treatment*. 2021 Jan;14:117863372110373.
58. Bale MI. Molecular Characterization of Methicillin-Resistant *Staphylococcus aureus* (MRSA) Isolated from Blood Samples of Patients Attending Selected Hospitals in Ilorin, Nigeria. *Kwara State University (Nigeria)*; 2021.

59. Liu Y. Investigating the prevalence and function of the *mecA* gene and PBP2a protein among *Staphylococcus* and *Mammaliicoccus* species. *Theoretical and Natural Science*. 2024;35:119–25.
60. Capasso C, Supuran CT. Sulfa and trimethoprim-like drugs-antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. *J Enzyme Inhib Med Chem*. 2014;29(3):379–87.
61. Alexander JAN, Chatterjee SS, Hamilton SM, Eltis LD, Chambers HF, Strynadka NCJ. Structural and kinetic analyses of penicillin-binding protein 4 (PBP4)-mediated antibiotic resistance in *Staphylococcus aureus*. *Journal of Biological Chemistry*. 2018;293(51):19854–65.
62. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. *Nat Rev Microbiol*.
63. Mohamed N, Timofeyeva Y, Jamrozy D, Rojas E, Hao L, Silmon de Monerri NC, et al. Molecular epidemiology and expression of capsular polysaccharides in *Staphylococcus aureus* clinical isolates in the United States. *PLoS One*. 2019;14(1):e0208356.
64. Andersen JL, He GX, Kakarla P, Ranjana KC, Kumar S, Lakra WS, et al. Multidrug efflux pumps from enterobacteriaceae, *Vibrio cholerae* and *Staphylococcus aureus* bacterial food pathogens. Vol. 12, *International Journal of Environmental Research and Public Health*. MDPI AG; 2015. p. 1487–547.
65. Dkh L, Mn H, Ar S. Interventions for the eradication of methicillin-resistant *Staphylococcus aureus* (MRSA) in people with cystic fibrosis (Review). 2015;
66. Lim WW, Wu P, Bond HS, Wong JY, Ni K, Seto WH, et al. Determinants of methicillin-resistant *Staphylococcus aureus* (MRSA) prevalence in the Asia-Pacific region: A systematic review and meta-analysis. Vol. 16, *Journal of Global Antimicrobial Resistance*. Elsevier Ltd; 2019. p. 17–27.
67. Torumkune D, Van PH, Thinh LQ, Koo SH, Tan SH, Lim PQ, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2016–18 in Vietnam, Cambodia, Singapore and the Philippines: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. *Journal of Antimicrobial Chemotherapy*. 2020;75(Supplement_1):i19–42.
68. Ajulo S, Awosile B. Global antimicrobial resistance and use surveillance system (GLASS 2022): Investigating the relationship between antimicrobial resistance and antimicrobial consumption data across the participating countries. *PLoS One*. 2024;19(2):e0297921.
69. Jesudason T. WHO publishes updated list of bacterial priority pathogens. *Lancet Microbe*. 2024;5(9).
70. WHO. WHO Media Centre. 2017. WHO publishes list of bacteria for which new antibiotics are urgently needed.
71. Chamas C. Global commitment to combat antimicrobial resistance. *Cad Saude Publica*. 2025;41:e00190924.
72. Ferber D. WHO advises kicking the livestock antibiotic habit. 2003 [cited 2019 Feb 16]; Available from: <http://science.sciencemag.org/content/301/5636/1027.short>